Alligator Bioscience AB

As of June 30, 2026, Alligator Bioscience AB carries a market capitalization of 72.37M, placing it among publicly traded companies globally. Its enterprise value stands at 85.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alligator Bioscience AB's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Alligator Bioscience AB has 628.11M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Alligator Bioscience AB maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 20, 2026, Alligator Bioscience AB's stock has declined approximately 97.98% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.29.

As of June 30, 2026, Alligator Bioscience AB holds 16.61M in cash and equivalents against 29.93M in total debt, resulting in a net debt position of -16.61M. Total book value stands at 3.33M, with working capital of -16.96M providing operational flexibility.

Alligator Bioscience AB's most recent stock split took place on September 1, 2026.